Novo Nordisk buys treatment candidate for rare disease for up to USD 1.2bn
Biotech company Prothena is selling the drug candidate treatment for ATTR amyloidosis. Novo Nordisk's initial focus is a particular variant of the disease which affects the heart.
BY ELIZABETH MØNSTED-JOHANSEN, TRANSLATED BY CATHERINE BRETT
Novo Nordisk has taken over Prothena's drug candidate PRX004, which is being developed to treat ATTR amyloidosis. In the same deal, Novo Nordisk is taking over Prothena's entire wide-ranging ATTR amyloidosis program.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
